Healthcare [ 7/13 ] | Diagnostics & Research [ 58/163 ]
NASDAQ | Common Stock
Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China.
It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC.
The company also provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients, as well as Magnis BR-customized version of its principal products.
In addition, it offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model.
Burning Rock Biotech Limited has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA.
The company was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 29, 24 | -1.65 Increased by +8.90% | -1.10 Decreased by -49.91% |
| Mar 29, 24 | -3.13 Decreased by -848.48% | -3.30 Increased by +5.15% |
| Nov 30, 23 | -1.71 Increased by +23.32% | -1.32 Decreased by -29.55% |
| Aug 31, 23 | -1.28 Increased by +48.80% | -1.86 Increased by +31.18% |
| May 30, 23 | -1.81 Increased by +27.60% | -2.45 Increased by +26.12% |
| Mar 28, 23 | -0.33 Increased by +86.25% | -0.35 Increased by +5.71% |
| Nov 15, 22 | -2.23 Decreased by -35.98% | -2.35 Increased by +5.11% |
| Aug 31, 22 | -2.50 Decreased by -27.55% | -2.40 Decreased by -4.17% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 121.08 M Decreased by -14.87% | -162.21 M Increased by +24.98% | Decreased by -133.97% Increased by +11.87% |
| Dec 31, 23 | 121.08 M Decreased by -15.04% | -162.21 M Increased by +12.44% | Decreased by -133.97% Decreased by -3.06% |
| Sep 30, 23 | 127.57 M Decreased by -17.50% | -174.98 M Increased by +22.68% | Decreased by -137.17% Increased by +6.28% |
| Jun 30, 23 | 146.27 M Decreased by -5.41% | -131.24 M Increased by +42.01% | Decreased by -89.73% Increased by +38.69% |
| Mar 31, 23 | 142.24 M Decreased by -3.47% | -216.22 M Increased by +13.90% | Decreased by -152.02% Increased by +10.81% |
| Dec 31, 22 | 142.52 M Increased by +5.16% | -185.25 M Increased by +28.19% | Decreased by -129.99% Increased by +31.71% |
| Sep 30, 22 | 154.63 M Increased by +22.13% | -226.31 M Decreased by -32.75% | Decreased by -146.35% Decreased by -8.70% |
| Jun 30, 22 | 154.63 M Increased by +21.49% | -226.31 M Decreased by -11.12% | Decreased by -146.35% Increased by +8.54% |